<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: We reviewed follow-up of patients treated in 19 randomized trials of adjuvant <z:chebi fb="0" ids="47898">epirubicin</z:chebi> in early <z:hpo ids='HP_0003002'>breast cancer</z:hpo> to determine incidence, risk, and risk factors for subsequent <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: The patients (N = 9,796) were observed from the start of adjuvant treatment (53,080 patient-years) </plain></SENT>
<SENT sid="2" pm="."><plain>Cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (<z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e>) were reported, with disease characteristics </plain></SENT>
<SENT sid="3" pm="."><plain>Incidence and cumulative risk were compared for possible risk factors, for assigned regimens, and for administered cumulative doses of <z:chebi fb="0" ids="47898">epirubicin</z:chebi> and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: In 7,110 patients treated with <z:chebi fb="0" ids="47898">epirubicin</z:chebi>-containing regimens (92% of whom also received <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>), 8-year cumulative probability of <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> was 0.55% (95% CI, 0.33% to 0.78%) </plain></SENT>
<SENT sid="5" pm="."><plain>The risk of developing <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> increased in relation to planned <z:chebi fb="0" ids="47898">epirubicin</z:chebi> dose per cycle, planned <z:chebi fb="0" ids="47898">epirubicin</z:chebi> dose-intensity, and administered cumulative doses of <z:chebi fb="0" ids="47898">epirubicin</z:chebi> and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Patients with administered cumulative doses of both <z:chebi fb="0" ids="47898">epirubicin</z:chebi> and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> not exceeding those used in standard regimens (&lt;/= 720 mg/m(2) and &lt;/= 6,300 mg/m(2), respectively) had an 8-year cumulative probability of developing <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> of 0.37% (95% CI, 0.13% to 0.61%) compared with 4.97% (95% CI, 2.06% to 7.87%) for patients administered higher cumulative doses of both <z:chebi fb="0" ids="47898">epirubicin</z:chebi> and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: Patients treated with standard cumulative doses of adjuvant <z:chebi fb="0" ids="47898">epirubicin</z:chebi> (&lt;/= 720 mg/m(2)) and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (&lt;/= 6,300 mg/m(2)) for early <z:hpo ids='HP_0003002'>breast cancer</z:hpo> have a lower probability of secondary <z:hpo ids='HP_0001909'>leukemia</z:hpo> than patients treated with higher cumulative doses </plain></SENT>
<SENT sid="8" pm="."><plain>Increased risk of secondary <z:hpo ids='HP_0001909'>leukemia</z:hpo> must be considered when assessing the potential benefit to risk ratio of higher than standard doses </plain></SENT>
</text></document>